The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review)

International Journal of Molecular Medicine

Volumn 32, Issue 6, 2013, Pages 1239-1246

  Liao, Yu Xin ^a   Zhou, Cheng Hao ^a   Zeng, Hui ^a   Zuo, Dong Qing ^a   Wang, Zhuo Ying ^a   Yin, Fei ^a   Hua, Ying Qing ^a   Cai, Zheng Dong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bone sarcoma; Chemokine 12; Chemokine receptor 4; Chemokine receptor 7; Chemokine receptors; Chemokines; Metastasis; Progression

Indexed keywords

CHEMOKINE; CHEMOKINE 12; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

BONE METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CHONDROSARCOMA; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

ANIMALS; BONE NEOPLASMS; CHEMOKINE CXCL12; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; OSTEOSARCOMA; RECEPTORS, CXCR; SIGNAL TRANSDUCTION;

EID: 84892146094     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1521     Document Type: Review

References (90)

1. Oda Y, Tateishi N, Matono H, et al: Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer 124: 1852-1859, 2009.
2. Kim RH, Li BD and Chu QD: The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma. Sarcoma 2011: 593708, 2011.
3. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
4. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC and Gebhardt MC: Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 429: 286-291, 2004.
5. Bentzen SM: Prognostic factor studies in oncology: osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys 49: 513-518, 2001.
6. Namløs HM, Kresse SH, Müller CR, et al: Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. Sarcoma 2012: 639038, 2012.
7. Clark JC, Akiyama T, Dass CR and Choong PF: New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis. Cancer Cell Int 10: 20, 2010.
8. Hemmati M, Abbaspour A, Alizadeh AM, et al: Rat xenograft chondrosarcoma development by human tissue fragment. Exp Oncol 33: 52-54, 2011.
9. Li TM, Lin TY, Hsu SF, et al: The novel benzimidazole derivative, MPTB, induces cell apoptosis in human chondrosarcoma cells. Mol Carcinog 50: 791-803, 2011.
10. Bergh P, Gunterberg B, Meis-Kindblom JM and Kindblom LG: Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: a center-based study of 69 cases. Cancer 91: 1201-1212, 2001.
11. Fiorenza F, Abudu A, Grimer RJ, et al: Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 84: 93-99, 2002.
12. Bruns J, Elbracht M and Niggemeyer O: Chondrosarcoma of bone: an oncological and functional follow-up study. Ann Oncol 12: 859-864, 2001.
13. Qureshi A, Ahmad Z, Azam M and Idrees R: Epidemiological data for common bone sarcomas. Asian Pac J Cancer Prev 11: 393-395, 2010.
14. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al: The clinical approach towards chondrosarcoma. Oncologist 13: 320-329, 2008.
15. Ozaki T, Hillmann A, Linder N, Blasius S and Winkelmann W: Metastasis of chondrosarcoma. J Cancer Res Clin Oncol 122: 625-628, 1996.
16. Berghuis D, Schilham MW, Santos SJ, et al: The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease. Clin Sarcoma Res 2: 24, 2012.
17. Hauer K, Calzada-Wack J, Steiger K, et al: DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. Cancer Res 73: 967-977, 2013.
18. Jin Z, Zhao C, Han X and Han Y: Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression. BMC Cancer 12: 480, 2012.
19. Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931, 2010.
20. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M and Yamamoto N: Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 60: 273-276, 2006.
21. Wang J, Loberg R and Taichman RS: The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 25: 573-587, 2006.
22. Sun X, Cheng G, Hao M, et al: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29: 709-722, 2010.
23. Le Y, Zhou Y, Iribarren P and Wang J: Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1: 95-104, 2004.
24. Liberman J, Sartelet H, Flahaut M, et al: Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS One 7: e43665, 2012.
25. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4: 540-550, 2004.
26. Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767, 2006.
27. Loetscher P, Moser B and Baggiolini M: Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol 74: 127-180, 2000.
28. + progenitors to peripheral blood. J Exp Med 185: 111-120, 1997.
29. Scotton CJ, Wilson JL, Scott K, et al: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62: 5930-5938, 2002.
30. Sun YX, Wang J, Shelburne CE, et al: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89: 462-473, 2003.
31. Smith MC, Luker KE, Garbow JR, et al: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64: 8604-8612, 2004.
32. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.
33. Zhou Y, Larsen PH, Hao C and Yong VW: CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 277: 49481-49487, 2002.
34. Barbero S, Bonavia R, Bajetto A, et al: Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 63: 1969-1974, 2003.
35. Hideshima T, Chauhan D, Hayashi T, et al: The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 1: 539-544, 2002.
36. Ponomaryov T, Peled A, Petit I, et al: Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106: 1331-1339, 2000.
37. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864, 2004.
38. Begley L, Monteleon C, Shah RB, Macdonald JW and Macoska JA: CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 4: 291-298, 2005.
39. Petit I, Szyper-Kravitz M, Nagler A, et al: G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3: 687-694, 2002.
40. Chinni SR, Sivalogan S, Dong Z, et al: CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66: 32-48, 2006.
41. Perissinotto E, Cavalloni G, Leone F, et al: Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 11: 490-497, 2005.
42. Feng Y, Broder CC, Kennedy PE and Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877, 1996.
43. Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL and Michael NL: Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem 273: 4754-4760, 1998.
44. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179, 2004.
45. Schioppa T, Uranchimeg B, Saccani A, et al: Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391-1402, 2003.
46. Zagzag D, Krishnamachary B, Yee H, et al: Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 65: 6178-6188, 2005.
47. Phillips RJ, Mestas J, Gharaee-Kermani M, et al: Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280: 22473-22481, 2005.
48. Bachelder RE, Wendt MA and Mercurio AM: Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62: 7203-7206, 2002.
49. Zagzag D, Lukyanov Y, Lan L, et al: Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86: 1221-1232, 2006.
50. Li YM, Pan Y, Wei Y, et al: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459-469, 2004.
51. Ao M, Franco OE, Park D, Raman D, Williams K and Hayward SW: Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67: 4244-4253, 2007.
52. Zhang L, Yeger H, Das B, Irwin MS and Baruchel S: Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia 9: 36-46, 2007.
53. Wang M, Wang L, Ren T, Xu L and Wen Z: IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biol Ther 14: 155-163, 2013.
54. Tang CH, Chuang JY, Fong YC, Maa MC, Way TD and Hung CH: Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 29: 1483-1492, 2008.
55. Huang CY, Lee CY, Chen MY, et al: Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol 221: 204-212, 2009.
56. Balabanian K, Lagane B, Infantino S, et al: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 35760-35766, 2005.
57. Burns JM, Summers BC, Wang Y, et al: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213, 2006.
58. Miao Z, Luker KE, Summers BC, et al: CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 104: 15735-15740, 2007.
59. Wang J, Shiozawa Y, Wang Y, et al: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 283: 4283-4294, 2008.
60. Kollmar O, Rupertus K, Scheuer C, et al: CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. Int J Cancer 126: 1302-1315, 2010.
61. Uto-Konomi A, McKibben B, Wirtz J, et al: CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4. Biochem Biophys Res Commun 431: 772-776, 2013.
62. Liekens S, Schols D and Hatse S: CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16: 3903-3920, 2010.
63. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D and Jain RK: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17: 2074-2080, 2011.
64. Gustin JA, Ozes ON, Akca H, et al: Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 279: 1615-1620, 2004.
65. Li Y, Chinni SR and Sarkar FH: Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10: 236-243, 2005.
66. Katiyar SK and Meeran SM: Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling. Free Radic Biol Med 42: 299-310, 2007.
67. Leelawat K, Leelawat S, Narong S and Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 13: 1561-1568, 2007.
68. Burger M, Glodek A, Hartmann T, et al: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22: 8093-8101, 2003.
69. Lai TH, Fong YC, Fu WM, Yang RS and Tang CH: Stromal cell-derived factor-1 increase alphavbeta3 integrin expression and invasion in human chondrosarcoma cells. J Cell Physiol 218: 334-342, 2009.
70. Ryu CH, Park SA, Kim SM, et al: Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. Biochem Biophys Res Commun 398: 105-110, 2010.
71. Heinrich EL, Lee W, Lu J, Lowy AM and Kim J: Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med 10: 68, 2012.
72. Laverdiere C, Hoang BH, Yang R, et al: Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11: 2561-2567, 2005.
73. Lin F, Zheng SE, Shen Z, et al: Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol 28: 649-653, 2011.
74. Baumhoer D, Smida J, Zillmer S, et al: Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma. Mod Pathol 25: 522-528, 2012.
75. Fan TM, Barger AM, Fredrickson RL, Fitzsimmons D and Garrett LD: Investigating CXCR4 expression in canine appendicular osteosarcoma. J Vet Intern Med 22: 602-608, 2008.
76. Oda Y, Yamamoto H, Tamiya S, et al: CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 19: 738-745, 2006.
77. Ma Q, Zhou Y, Ma B, et al: The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. Oncol Lett 3: 797-801, 2012.
78. Bai S, Wang D, Klein MJ and Siegal GP: Characterization of CXCR4 expression in chondrosarcoma of bone. Arch Pathol Lab Med 135: 753-758, 2011.
79. Bennani-Baiti IM, Cooper A, Lawlor ER, et al: Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer Res 16: 3769-3778, 2010.
80. Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297, 2008.
81. Kim SY, Lee CH, Midura BV, et al: Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25: 201-211, 2008.
82. de Nigris F, Rossiello R, Schiano C, et al: Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res 68: 1797-1808, 2008.
83. Miura K, Uniyal S, Leabu M, et al: Chemokine receptor CXCR4-β1 integrin axis mediates tumorigenesis of osteosarcoma HOS cells. Biochem Cell Biol 83: 36-48, 2005.
84. Hendrix CW, Collier AC, Lederman MM, et al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253-1262, 2004.
85. De Clercq E: The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 77: 1655-1664, 2009.
86. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 22: 1095-1102, 2004.
87. Cashen A, Lopez S, Gao F, et al: A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 14: 1253-1261, 2008.
88. Kim HY, Hwang JY, Kim SW, et al: The CXCR4 antagonist AMD3100 has dual effects on survival and proliferation of myeloma cells in vitro. Cancer Res Treat 42: 225-234, 2010.
89. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS and Heveker N: AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75: 1240-1247, 2009.
90. Lapteva N, Yang AG, Sanders DE, Strube RW and Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12: 84-89, 2005.